In treatment trials for major depressive disorder (MDD), early symptom improvement is predictive of eventual clinical response. Clinical response may also be predicted by elevated pretreatment theta (4-7 Hz) current density in the rostral anterior cingulate (rACC) and medial orbitofrontal cortex (mOFC). We investigated the relationship between pretreatment EEG and early improvement in predicting clinical outcome in 72 MDD subjects across three placebo-controlled treatment trials. Subjects were randomized to receive fluoxetine, venlafaxine, or placebo. Theta current density in the rACC and mOFC was computed with Low-Resolution Brain Electromagnetic Tomography (LORETA). An analysis of covariance examining week-8 Hamilton Depression Rating Scale (HamD) percent change, showed a significant effect of week-2 HamD percent change, and a significant three-way interaction of week-2 HamD percent change×treatment × rACC. Medication subjects with robust early improvement showed almost no relationship between rACC theta current density and final clinical outcome. However, in subjects with little early improvement, rACC activity showed a strong relationship with clinical outcome. The model examining the mOFC showed a trend in the three-way interaction. A combination of pretreatment rACC activity and early symptom improvement may be useful for predicting treatment response.
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Introduction
Major depressive disorder (MDD) is difficult to treat because there is no accepted method to predict which treatment will benefit a particular patient. The current trial-and-error strategy for medication selection (Fochtman and Gelenberg, 2005) eventually leads to response for the majority of patients, but patients may have less than a 30% chance of recovery with an initial trial of an antidepressant medication (Trivedi et al., 2006) . Recovery from depression would be hastened by development of predictors that could be measured prior to treatment or early in the course of treatment (Leuchter et al., 2009b) . Such predictors include pretreatment regional brain activity, as well as early improvement in symptoms (Leuchter et al., 2009b) .
Prior reports, using various neuroimaging techniques, have shown that subjects who ultimately respond to antidepressant treatment typically have elevated pretreatment metabolic activity in the rostral anterior cingulate (rACC) and medial orbitofrontal cortex (mOFC), as demonstrated with positron emission tomography (PET) (Mayberg et al., 1997; Saxena et al., 2003) , or increased theta current density as measured using quantitative electroencephalography (QEEG) (Pizzagalli et al., 2001; Mulert et al., 2007; Korb et al., 2009) . Theta current density studies have utilized Low-Resolution Brain Electromagnetic Tomography (LORETA), which is a widely used and well-validated QEEG source-localization algorithm (Seeck et al., 1998; Worrell et al., 2000; Oakes et al., 2004) . It is not surprising that responders differ from non-responders in both glucose metabolism and theta current density, given that rACC theta current density has been shown to correlate with rACC metabolism (Oakes et al., 2004) .
In addition to the predictions of pretreatment brain activity, numerous reports also have demonstrated a strong relationship between eventual response and symptom improvement in the first 2 weeks of treatment (Szegedi et al., 2003; Katz et al., 2004; Papakostas et al., 2007; Stassen et al., 2007; Szegedi et al., 2009) . Conversely, the absence of early improvement during pharmacotherapy is associated with poor 8-week outcome (Nierenberg et al., 1995; Szegedi et al., 2009) , although the lack of specificity of these changes limits the usefulness of this measure as a sole predictor (Leuchter et al., 2009b; Szegedi et al., 2009) . Whereas distinct lines of research have identified brain function and early symptom improvement as predictors of response, the relationship between these predictors is unknown. Understanding whether early improvement in symptoms is linked to, or independent of, rACC or mOFC activity is important in determining how these predictors could potentially be employed in clinical practice.
While elevated baseline activity in rACC and mOFC have each been associated with greater likelihood of clinical response, the relationship between pretreatment rACC/mOFC activity and early improvement Psychiatry Research: Neuroimaging 192 (2011) 188-194 
